The enhanced efficacy of the dual-drug ADC was also confirmed in the HCC1954-TDR xenograft mouse model, another model representing a low-HER2 breast tumor with intratumor heterogeneity and resistance to T-DM1. The gene discussed is ERBB2; the disease is breast neoplasm.